Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ...

The CBSE Class 10 exams will take place between February 17 and March 10, and the Class 12 exams will be conducted from ...

Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint ...

Q3 2025 Earnings Call Transcript November 13, 2025 Protalix BioTherapeutics, Inc. misses on earnings expectations. Reported ...

Presented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after systemic administration; data also demonstrates that the platform ...

Medicxi, a leading European life sciences venture capital firm, today announced the closing of Medicxi V, a €500 million fund dedicated ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

Adjusted EBITDA from continuing operations of $1.2 million for the nine months ended September 30, 2025, compared to a loss of $0.1 million in the year ago period ...

Presented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after systemic administration; data also demonstrates that the platform ...

Arcutis Biotherapeutics announced strong third-quarter 2025 results, reporting revenue of $99.2 million and achieving profitability for the first time, which surpassed analyst expectations. Following ...

Secures royalty economic interests in two early stage partnered assets through XOMA Royalty’s announced expected ...

A research team at the University of Cologne examined how optional support influences students' learning success and ...